MedTrace Logo

Immunosuppression Reduction in Failed Allograft Guided by cfDNA

NCT04560582 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-11-29

No results posted yet for this study

Summary

The optimal timing for immunosuppression tapering for patients with failed kidney transplant is not known. This pilot study would be to correlate rise in cf-DNA and increase in cPRA.

Conditions

  • Kidney Transplant; Complications
  • Kidney Transplant Rejection
  • Kidney Transplant Failure

Interventions

PROCEDURE

Blood Draw

Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Adam Bregman, MD · University of Minenesota

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-22
Primary Completion
2023-09-30
Completion
2023-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04560582 on ClinicalTrials.gov